Sun Pharmaceutical Industries liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

12.56×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.82×	2.82×	2.89×	2.56×	2.00×
2.31×	2.31×	2.33×	1.98×	1.47×
31,603	30,704	23,925	17,870	13,996
45,675	41,238	34,400	26,449	19,956

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUNPHARMA₹1,761.00

Sun Pharmaceutical Industries Ltd.

· Pharma & Health

₹ CrorePeersCIPLA DRREDDY LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹4.23L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	12.56
Current Ratio	2.00	2.56	2.89	2.82	2.82
Quick Ratio	1.47	1.98	2.33	2.31	2.31
Cash, Equiv & ST Investments	13,996.3	17,870.2	23,924.9	30,704.0	31,602.7
Working Capital	19,955.6	26,449.3	34,399.9	41,238.3	45,675.0

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 199%.